- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Atopic dermatitis
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Nemolizumab – March 2026
Powder for injection containing nemolizumab 30 mg with diluent in pre-filled dual-chamber pen
Last updated
11 March 2026
